Psoriasis: Genetic associations and immune system changes

Genes and Immunity

Volumn 8, Issue 1, 2007, Pages 1-12

  Liu, Y ^a   Krueger, J G ^b   Bowcock, A M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANTIPSORIASIS AGENT; BETA DEFENSIN; BETA1 INTEGRIN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CNTO 1275; CORTICOSTEROID; ETANERCEPT; GAMMA INTERFERON; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLATELET DERIVED GROWTH FACTOR; SECONDARY LYMPHOID TISSUE CHEMOKINE; SOMATOMEDIN C RECEPTOR; STROMAL CELL DERIVED FACTOR 1; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANTIGEN EXPRESSION; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG TARGETING; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATORY INFILTRATE; KERATINOCYTE; NUCLEOTIDE SEQUENCE; PENETRANCE; PRIORITY JOURNAL; PSORIASIS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN EXFOLIATION; T LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOIMMUNE DISEASES; CHRONIC DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; KERATINOCYTES; PSORIASIS; SKIN; VARIATION (GENETICS);

EID: 33846500207     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364351     Document Type: Review

References (99)

1. Barisic-Drusko V, Rucevic I. Trigger factors in childhood psoriasis and vitiligo. Coll Antropol 2004; 28: 277-285.
2. Quesada JR, Gutterman JU. Psoriasis and alpha-interferon. Lancet 1986; 1: 1466-1468.
3. Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, Burg G et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004; 140: 1490-1495.
4. Zhou X, Krueger JG, Kao MC, Lee E, Du F, Menter A et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003; 13: 69-78.
5. Mansbridge JN, Knapp AM. Changes in keratinocyte maturation during wound healing. J Invest Dermatol 1987; 89: 253-263.
6. Hertle MD, Kubler MD, Leigh IM, Watt FM. Aberrant integrin expression during epidermal wound healing and in psoriatic epidermis. J Clin Invest 1992; 89: 1892-1901.
7. Krane JF, Gottlieb AB, Carter DM, Krueger JG. The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor. J Exp Med 1992; 175: 1081-1090.
8. Ghadially R, Reed JT, Elias PM. Stratum corneum structure and function correlates with phenotype in psoriasis. J Invest Dermatol 1996; 107: 558-564.
9. Allen M, Ishida-Yamamoto A, McGrath J, Davison S, Iizuka H, Simon M et al. Corneodesmosin expression in psoriasis vulgaris differs from normal skin and other inflammatory skin disorders. Lab Invest 2001; 81: 969-976.
10. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192: 681-694.
11. Ansel JC, Tiesman JP, Olerud JE, Krueger JG, Krane JF, Tara DC et al. Human keratinocytes are a major source of cutaneous platelet-derived growth factor. J Clin Invest 1993; 92: 671-678.
12. Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992; 176: 1375-1379.
13. Viac J, Palacio S, Schmitt D, Claudy A. Expression of vascular endothelial growth factor in normal epidermis, epithelial tumors and cultured keratinocytes. Arch Dermatol Res 1997; 289: 158-163.
14. Eckert RL, Broome AM, Ruse M, Robinson N, Ryan D, Lee K. S100 proteins in the epidermis. J Invest Dermatol 2004; 123: 23-33.
15. Banno T, Adachi M, Mukkamala L, Blumenberg M. Unique keratinocyte-specific effects of interferon-gamma that protect skin from viruses, identified using transcriptional profiling. Antivir Ther 2003; 8: 541-554.
16. Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 2004; 279: 32633-32642.
17. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: Blood and skin comparisons by flow cytometry. J Autoimmun 2000; 14: 63-78.
18. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113: 752-759.
19. Vissers WH, Arndtz CH, Muys L, Van Erp PE, de Jong EM, van de Kerkhof PC. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol 2004; 150: 852-859.
20. Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, Kapsenberg ML. Predominance of 'memory' T cells (CD4+, CDw29+) over 'naive' T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res 1989; 281: 24-30.
21. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest 2001; 81: 335-347.
22. Austin LM, Coven TR, Bhardwaj N, Steinman R, Krueger JG. Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis. J Cutan Pathol 1998; 25: 79-88.
23. Yawalkar N, Schmid S, Braathen LR, Pichler WJ. Perforin and granzyme B may contribute to skin inflammation in atopic dermatitis and psoriasis. Br J Dermatol 2001; 144: 1133-1139.
24. Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 2005; 102: 2075-2080.
25. Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005; 102: 19057-19062.
26. Wang F, Lee E, Lowes MA, Haider AS, Fuentes-Duculan J, Abello MV et al. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: Gene regulation and cellular effects. J Invest Dermatol 2006; 126: 1590-1599.
27. Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest 1994; 94: 202-209.
28. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199: 125-130.
29. Wollenberg A, Wagner M, Gunther S, Towarowski A, Tuma E, Moderer M et al. Plasmacytoid dendritic cells: A new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002; 119: 1096-1102.
30. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910-1914.
31. Teunissen MB, Koomen CW, de Waal Malefyt R,Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111: 645-649.
32. Bowcock AM, Krueger JG. Getting under the skin: The immunogenetics of psoriasis. Nat Rev Immunol 2005; 5: 699-711.
33. Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: Cutaneous lymphoid tissue supports T-cell activation and 'Type 1' inflammatory gene expression. Trends Immunol 2004; 25: 295-305.
34. Lowes MA, Lew W, Krueger JG. Current concepts in the immunopathogenesis of psoriasis. Dermatol Clin 2004; 22: 349-369, vii.
35. Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004; 123: 1037-1044.
36. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006; 33: 1447-1451.
37. Ragaz A, Ackerman AB. Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. Am J Dermatopathol 1979; 1: 199-214.
38. Kurth I, Willimann K, Schaerli P, Hunziker T, Clark-Lewis I, Moser B. Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med 2001; 194: 855-861.
39. Elder JT, Nair RP, Guo SW, Henseler T, Christophers E, Voorhees JJ. The genetics of psoriasis. Arch Dermatol 1994; 130: 216-224.
40. Bowcock AM. Psoriasis genetics: The way forward. J Invest Dermatol 2004; 122: Xv-xvii.
41. Tiilikainen A, Lassus A, Karvonen J, Vartiainen P, Julin M. Psoriasis and HLA-Cw6. Br J Dermatol 1980; 102: 179-184.
42. Asumalahti K, Veal C, Laitinen T, Suomela S, Allen M, Elomaa O et al. Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. Hum Mol Genet 2002; 11: 589-597.
43. Allen MH, Veal C, Faassen A, Powis SH, Vaughan RW, Trembath RC et al. A non-HLA gene within the MHC in psoriasis. Lancet 1999; 353: 1589-1590.
44. Guerrin M, Vincent C, Simon M, Tazi Ahnini R, Fort M, Serre G. Identification of six novel polymorphisms in the human corneodesmosin gene. Tissue Antigens 2001; 57: 32-38.
45. Tazi Ahnini R, Camp NJ, Cork MJ, Mee JB, Keohane SG, Duff GW et al. Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis. Hum Mol Genet 1999; 8: 1135-1140.
46. Simon M, Jonca N, Guerrin M, Haftek M, Bernard D, Caubet C et al. Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation. J Biol Chem 2001; 276: 20292-20299.
47. Jonca N, Guerrin M, Hadjiolova K, Caubet C, Gallinaro H, Simon M et al. Corneodesmosin, a component of epidermal corneocyte desmosomes, displays homophilic adhesive properties. J Biol Chem 2002; 277: 5024-5029.
48. Gallinaro H, Jonca N, Langbein L, Vincent C, Simon M, Serre G et al. A 4.2 kb upstream region of the human corneodesmosin gene directs site-specific expression in hair follicles and hyperkeratotic epidermis of transgenic mice. J Invest Dermatol 2004; 122: 730-738.
49. Veal CD, Capon F, Allen MH, Heath EK, Evans JC, Jones A et al. Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. Am J Hum Genet 2002; 71: 554-564.
50. Helms C, Saccone NL, Cao L, Daw JA, Cao K, Hsu TM et al. Localization of PSORS1 to a haplotype block harboring HLAC and distinct from corneodesmosin and HCR. Hum Genet 2005; 118: 466-476.
51. Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006; 78: 827-851.
52. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P. A haplotype map of the human genome. Nature 2005; 437: 1299-1320.
53. Asumalahti K, Laitinen T, Lahermo P, Suomela S, Itkonen-Vatjus R, Jansen C et al. Psoriasis susceptibility locus on 18p revealed by genome scan in Finnish families not associated with PSORS1. J Invest Dermatol 2003; 121: 735-740.
54. Tomfohrde J, Silverman A, Barnes R, Fernandez-Vina MA, Young M, Lory D et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994; 264: 1141-1145.
55. Tzschach A, Hoffmann K, Hoeltzenbein M, Bache I, Tommerup N, Bommer C et al. Molecular characterization of a balanced chromosome translocation in psoriasis vulgaris. Clin Genet 2006; 69: 189-193.
56. Hwu WL, Yang CF, Fann CS, Chen CL, Tsai TF, Chien YH et al. Mapping of psoriasis to 17q terminus. J Med Genet 2005; 42: 152-158.
57. Birnbaum RY, Zvulunov A, Hallel-Halevy D, Cagnano E, Finer G, Ofir R et al. Seborrhea-like dermatitis with psoriasiform elements caused by a mutation in ZNF750, encoding a putative C2H2 zinc finger protein. Nat Genet 2006; 38: 749-751.
58. Helms C, Cao L, Krueger JG, Wijsman EM, Chamian F, Gordon D et al. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis (see comment). Nat Genet 2003; 35: 349-356.
59. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002; 32: 666-669.
60. Tokuhiro S, Yamada R, Chang X, Suzuki A, Kochi Y, Sawada T et al. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis (see comment). Nat Genet 2003; 35: 341-348.
61. Coffman JA. Runx transcription factors and the develop mental balance between cell proliferation and differentiation. Cell Biol Int 2003; 27: 315-324.
62. Osato M, Yanagida M, Shigesada K, Ito Y. Point mutations of the RUNx1/ AML1 gene in sporadic and familial myeloid leukemias. Int J Hematol 2001; 74: 245-251.
63. Fainaru O, Woolf E, Lotem J, Yarmus M, Brenner O, Goldenberg D et al. Runx3 regulates mouse TGF-betamediated dendritic cell function and its absence results in airway inflammation. EMBO J 2004; 23: 969-979.
64. Brenner O, Levanon D, Negreanu V, Golubkov O, Fainaru O, Woolf E et al. Loss of Runx3 function in leukocytes is associated with spontaneously developed colitis and gastric mucosal hyperplasia. Proc Natl Acad Sci USA 2004; 101: 16016-16021.
65. Grueter B, Petter M, Egawa T, Laule-Kilian K, Aldrian CJ, Wuerch A et al. Runx3 regulates integrin alpha E/CD103 and CD4 expression during development of CD4-/CD8+ T cells. J Immunol 2005; 175: 1694-1705.
66. Capon F, Helms C, Veal CD, Tillman D, Burden AD, Barker JN et al. Genetic analysis of PSORS2 markers in a UK dataset supports the association between RAPTOR SNPs and familial psoriasis. J Med Genet 2004; 41: 459-460.
67. Hewett D, Samuelsson L, Polding J, Enlund F, Smart D, Cantone K et al. Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics 2002; 79: 305-314.
68. Hebert SC, Mount DB, Gamba G. Molecular physiology of cation-coupled Cl-cotransport: The SLC12 family. Pflugers Arch 2004; 447: 580-593.
69. Huffmeier U, Lascorz J, Traupe H, Bohm B, Schurmeier-Horst F, Stander M et al. Systematic linkage disequilibrium analysis of SLC12A8 at PSORS5 confirms a role in susceptibility to psoriasis vulgaris. J Invest Dermatol 2005; 125: 906-912.
70. Capon F, Novelli G, Semprini S, Clementi M, Nudo M, Vultaggio P et al. Searching for psoriasis susceptibility genes in Italy: Genome scan and evidence for a new locus on chromosome 1. J Invest Dermatol 1999; 112: 32-35.
71. Bhalerao J, Bowcock AM. The genetics of psoriasis: A complex disorder of the skin and immune system. Hum Mol Genet 1998; 7: 1537-1545.
72. Capon F, Semprini S, Dallapiccola B, Novelli G. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet 1999; 65: 1798-1800.
73. Cookson WO, Ubhi B, Lawrence R, Abecasis GR, Walley AJ, Cox HE et al. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet 2001; 27: 372-373.
74. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-446.
75. Morar N, Bowcock AM, Harper JI, Cookson WO, Moffatt MF. Investigation of the chromosome 17q25 PSORS2 locus in atopic dermatitis. J Invest Dermatol 2006; 126: 603-606.
76. Sagoo GS, Tazi-Ahnini R, Barker JW, Elder JT, Nair RP, Samuelsson L et al. Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. J Invest Dermatol 2004; 122: 1401-1405.
77. Foerster J, Nolte I, Schweiger S, Ehlert C, Bruinenberg M, Spaar K et al. Evaluation of the IRF-2 gene as a candidate for PSORS3. J Invest Dermatol 2004; 122: 61-64.
78. Yan KL, Zhang XJ, Wang ZM, Yang S, Zhang GL, Wang J et al. A novel MGST2 non-synonymous mutation in a Chinese pedigree with psoriasis vulgaris. J Invest Dermatol 2006; 126: 1003-1005.
79. Yang S, Yan KL, Zhang XJ, Xiao FL, Fan X, Gao M et al. Systematic evaluation of association between the microsomal glutathione S-transferase 2 common variation and psoriasis vulgaris in Chinese population. Arch Dermatol Res 2006; 298: 107-112.
80. Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison WE, McFarland HF et al. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci USA 1998; 95: 9979-9984.
81. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC et al. A missense singlenucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004; 75: 330-337.
82. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36: 337-338.
83. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004; 75: 504-507.
84. Huffmeier U, Steffens M, Burkhardt H, Lascorz J, Schurmeier-Horst F, Stander M et al. Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients. J Med Genet 2006; 43: 517-522.
85. Guo D, Li M, Zhang Y, Yang P, Eckenrode S, Hopkins D et al. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet 2004; 36: 837-841.
86. Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 2005; 124: 1275-1283.
87. Mossner R, Kingo K, Kleensang A, Kruger U, Konig IR, Silm H et al. Association of TNF-238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol 2005; 124: 282-284.
88. Reich K, Westphal G, Schulz T, Muller M, Zipprich S, Fuchs T et al. Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. J Invest Dermatol 1999; 113: 214-220.
89. Litjens NH, van der Plas MJ, Ravensbergen B, Numan-Ruberg SC, van Assen Y, Thio HB et al. Psoriasis is not associated with IL-12p70/IL-12p40 production and IL12B promoter polymorphism. J Invest Dermatol 2004; 122: 923-926.
90. Tsunemi Y, Saeki H, Nakamura K, Sekiya T, Hirai K, Fujita H et al. Interleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci 2002; 30: 161-166.
91. Begovich AB, Schrodi SJ, Leppert M, Krueger G, Cargill M. A genome-wide association study of putative functional SNPs leads to the identification of two psoriasis loci - IL12B and IL23R - in 3 independent white North American sample sets. Am J Hum Genet 2006; Society meeting abstracts: A163.
92. Trinchieri G. Cytokines and cytokine receptors. Immunol Rev 2004; 202: 5-7.
93. Beissert S, Ruhlemann D, Mohammad T, Grabbe S, El-Ghorr A, Norval M et al. IL-12 prevents the inhibitory effects of cisurocanic acid on tumor antigen presentation by Langerhans cells: Implications for photocarcinogenesis. J Immunol 2001; 167: 6232-6238.
94. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132.
95. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441: 231-234.
96. Koks S, Kingo K, Vabrit K, Ratsep R, Karelson M, Silm H et al. Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis. Genes Immun 2005; 6: 407-415.
97. Asadullah K, Eskdale J, Wiese A, Gallagher G, Friedrich M, Sterry W. Interleukin-10 promoter polymorphism in psoriasis. J Invest Dermatol 2001; 116: 975-978.
98. Hensen P, Asadullah K, Windemuth C, Ruschendorf F, Huffmeier U, Stander M et al. Interleukin-10 promoter polymorphism IL10.G and familial early onset psoriasis. Br J Dermatol 2003; 149: 381-385.
99. Kingo K, Koks S, Silm H, Vasar E. IL-10 promoter polymorphisms influence disease severity and course in psoriasis. Genes Immun 2003; 4: 455-457.